New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
06:44 EDTSHPGShire price target raised to $196 from $174 at Piper Jaffray
Piper Jaffray raised its price target for Shire shares to $196 following the company's better than expected Q4 results and reiterates an Overweight rating on the stock.
News For SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
13:58 EDTSHPGShire initiated with a Reduce at HSBC
Price target GBP 47.34.
June 15, 2015
07:02 EDTSHPGArmaGen achieves clinical milestone in collaboration with Shire
ArmaGen announced that it achieved a clinical milestone in its worldwide licensing and collaboration agreement with Shire. The milestone was achieved in conjunction with dosing patients in its Phase 1 clinical trial of AGT-182, an investigational treatment of Hunter syndrome, and under terms of the agreement, the Company is entitled to a milestone payment from Shire. Also known as MPS II, Hunter syndrome is a rare, severe, progressive and life-limiting lysosomal storage disorder. The primary objective of the Phase 1 trial is to test the safety and determine a well-tolerated dose of AGT-182, an investigational enzyme replacement therapy, in adult patients with Hunter syndrome. ArmaGen plans to enroll 12 patients 18 years and older into the study. These patients will be treated for a total of eight weeks, with all enrolled patients receiving AGT-182.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use